Oruka Therapeutics, Inc. (ORKA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-04-30) · 99.1 | ||
| 10-KLatest | FY-2025 | — | ||
| 10-Q | Q3-2025 | — | ||
| 10-Q | Q2-2025 | — | ||
| 10-Q | Q1-2025 | — | ||
| 10-K | FY-2024 | — | ||
| 10-Q | Q3-2024 | 8-K (2024-09-05) · 99.1 · 99.2 · 99.3 · 99.4 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-01) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-04-25) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-01) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-10-18) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | ||
| Audit Information | — |
|
| Statements | ||
| Balance Sheets | ||
| Consolidated Balance Sheets | ||
| Balance Sheets (P) | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statement of Operations and Comprehensive Loss | ||
| Consolidated Statements of Operations | ||
| Statements of Operations | ||
| Consolidated Statement of Operations and Comprehensive Loss (P) | ||
| Consolidated Statements of Operations (P) | ||
| Statements of Operations (P) | ||
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (deficit) (unaudited) | — |
|
| Consolidated Statements of Comprehensive Loss | ||
| Statements of Stockholders' Equity | ||
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (deficit) (unaudited) (P) | — |
|
| Consolidated Statement of Convertible Preferred Stock and Stockholders Equity | ||
| Statements of Cash Flows | ||
| Consolidated Statement of Cash Flows | ||
| Consolidated Statement of Convertible Preferred Stock and Stockholders Equity (P) | — |
|
| Notes | ||
| 401(k) Plan | — |
|
| Accrued Expenses and Other Current Liabilities | ||
| Atm Offering | ||
| Cash Equivalents and Marketable Securities | ||
| Commitments and Contingencies | ||
| Convertible Preferred Stock and Stockholders Equity | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Employee Benefit Plans | — |
|
| Equity Financings | ||
| Fair Value Disclosures | ||
| Fair Value Measurements | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Merger Agreement | — |
|
| Nature of The Business and Basis of Presentation | ||
| Net Loss Per Share | ||
| Note Payable With Related Party | ||
| Option Agreements | — |
|
| Option Agreements and License Agreements | ||
| Pay Vs Performance Disclosure | ||
| Pipe Financings | — |
|
| Property and Equipment | ||
| Related Party Arrangements | ||
| Related Party Transactions | ||
| Reverse Recapitalization and Pre-closing Financing | ||
| Segment Disclosures | ||
| Share-based Compensation | ||
| Stock-based Compensation | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| The Company and Summary of Significant Accounting Policies | ||